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Objectives

• To reduce the time needed for Niemann-Pick Type C (NPC) diagnosis

• To identify the classic NPC symptoms in children

• To encourage the multispecialty collaboration when NPC is suspected

• To describe the current management and treatment options for NPC

Introduction to Niemann-Pick Disease

Niemann-Pick Disease
• Inherited condition involving abnormal lipid metabolism

• Harmful amounts of lipids accumulate in the
spleen, liver, lungs, bone marrow, and brain

• Autosomal recessive pattern of inheritance
(two copies of the gene must be present)

• Four variants: A, B, C1, and C2

Vanier MT. Niemann-Pick Diseases. In: Dulac O, Lassonde M, Sarnat HB, eds. Handbook of Clinical Neurology. 3rd ed. Elsevier B.V; 2013:1717-21.

Niemann-Pick Disease
Two distinct entities
Types A and B: mutated SMPD1 gene
•

SMPD gene carries instructions for cells to produce
sphingomyelinase, which processes lipids

•

Mutations lead to deficiency of sphingomyelinase and
accumulation of cholesterol and lipids

Types C1 and C2: mutated NPC1 or NPC2 gene
•

NPC1 gene encodes a protein that plays a critical role in
regulation of intracellular cholesterol trafficking

•

NPC2 gene encodes a protein that binds and transports
cholesterol (this is not fully understood)

Vanier MT. Niemann-Pick Diseases. In: Dulac O, Lassonde M, Sarnat HB, eds. Handbook of Clinical Neurology. 3rd ed. Elsevier B.V; 2013:1717-21.

Niemann-Pick Disease Type C

Niemann-Pick Type C (NPC) is a Fatal,
Progressive, Neurodegenerative Disorder
• NPC occurs with a minimal incidence of 1:120,000 live births1
– This number is based on 63 cases diagnosed in French hospitals between 20002009 versus the number of total births during this period
– The prevalence is higher (1:104,000) when including prenatal cases from terminated
pregnancies

• This is considered an under-estimate of the true prevalence of NPC, as
atypical phenotypes may be not be clinically suspected1
• There are reports that the prevalence of NPC is approximately 500
patients worldwide and 200 patients in the United States2,3

1. Vanier MC, et al. Orphanet J Rare Dis. 2010;5(16):1-18. 2. National Niemann-Pick Disease Foundation Inc. http://nnpdf.org/overview/#NPC Accessed June 29, 2017. 3. Miglustat therapy for
Nieman-Pick Type C disease. UCM248677.
https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM248677.pdf. Accessed June 29, 2017.

In Most Cases, NPC is Caused by Mutations in Two Genes:
NPC1 (95% of Cases) or NPC2 (5% of Cases)

• The Niemann-Pick type C1 (NPC1) gene is responsible for most (~95%) cases of NPC
disease1
– NPC1 is located on chromosome 18 at cytogenetic band 18q11-122,3
– NPC2 is mapped at chromosome 14q24.3

• The NPC1 gene encodes a small soluble lysosomal protein involved in cholesterol
binding3

1. Vanier MT, et al. Am J Hum Genet. 1996;58:118-25. 2. Carstea ED, et al. Science. 1997;277:228-31. 3. Ioannou YA. Mol Genet Metab 2000;71(1-2):175-81.

In Most Cases, NPC is Caused by Mutations in Two Genes:
of (5%
the NPC1
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NPC1 (95% ofTopological
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of Cases),
cont.
of NPC1 mutations
• Both NPC1 and NPC2 have identical biochemical patterns, suggesting that the two
proteins function together in cellular transport of cholesterol, glycolipids, etc1
– Their precise functions and relationship remain unclear and are currently the subject of intense
investigation

• NPC mutations result in intracellular lipid accumulation in various tissues, including the
brain, liver, and spleen1,2
Topological model of the NPC1 protein
and locations of NPC1 mutations

Figure reproduced from Vanier MT, Millat G. Clin Genet 2003;64(4):269-81.
Figure reproduced from Vanier MT, Millat G. Clin Genet 2003;64(4):269-81.
1. Maue RA, et al. Hum Mol Genet. 2012;21(4):730-50. 2. Praggastis M, et al. J Neurosci. 2015;35(21):8091-106.

Pathophysiology

In NPC Disease, the Cholesterol
Central Biochemical
Defect
is cell
Impaired Intracellular
uptake and processing
in the
Lipid Trafficking
• NPC1 is a transmembrane protein located on the LE/L
compartments where it regulates cholesterol efflux

Cholesterol uptake and processing in the cell

• The cholesterol trafficking defect occurs when
endocytosed LDL-cholesterol becomes sequestered in
lysosomes around the cell nucleus
• Transport from these perinuclear lysosomes is delayed,
resulting in excess accumulation of unesterified
cholesterol

• This accumulation may result in a deficiency in cell
membrane cholesterol with subsequent membrane
dysfunction/a triggering of apoptosis

Figure reproduced from Liu B, et al. J Lipid Res. 2007;48(8):1710-23.

LDL, low-density lipoprotein; LDLR, low-density lipoprotein receptor;Figure
LE, late
endosomes;
L, lysosomes.
reproduced
from
Liu B, et al. J Lipid Res. 2007;48(8):1710-23.
Maetzel D, et al. Stem Cell Reports. 2014:2(6):866-880. 2. Liu B. Clin Lipidol. 2012;7:289-301.

The NPC1 Deletion (NPC1-/-) Mouse Model Demonstrates Accumulation
of Cholesterol Within Tissues1,2
• Loss-of-function mutation in either NPC1 or NPC2 results in disruption of cholesterol
transport out of the LE/L, causing accumulation of cholesterol
• Cholesterol accumulation was ~7-fold greater in NPC1-/- mice compared with control
animals, due to daily sequestration of 67 mg cholesterol per kg in various organs 2
• LDL uptake from the circulation was not altered in NPC1-/- mice, and cholesterol
absorption was not increased2
• Furthermore, administration of a sterol-binding agent to NPC1-/- mice increased
cholesterol movement out of the LE/L in the liver from near 0 to 233 mg/day/kg3
• This suggests that NPC1 deletion causes accumulation of cholesterol by disrupting
cholesterol transport out of the LE/L

LE, late endosomes; L, lysosomes
1. Liu B, et al. J Lipid Res. 2007;48(8):1710-23. 2. Xie C, et al. Proc Natl Acad Sci USA. 1999;96(21):11992-7. 3. Liu B, et al. Proc Natl Acad Sci USA. 2009;106(7):2377-82.

Animal and Organ Weights, Cholesterol Pool Sizes, and Rates of Dietary
Cholesterol Absorption in NPC1-/- Mice
NPC+/+/
LDLR+/+

NPC-/-/
LDLR+/+

Weight of whole animal, g

21.3 ± 0.3

17.4 ± 0.3a

Weight of liver, g

1.20 ± 0.03

1.33 ±0.037a

Weight of brain, g

0.44 ±0.01

0.38 ± 0.03a

Cholesterol pool at day 1, mg/kg

1725 ± 22

2453 ± 35a

Cholesterol pool at 7 weeks, mg/kg

2165 ± 47

5669 ± 173a

9.2

67.0

14 ± 2

8 ± 2a

Cholesterol sequestration, mg/day per kg
Cholesterol absorption, mg/day per kg

aSignificant

difference between NPC-/- / LDLR+/+ and control (NPC+/+ / LDLR+/+) mice.
Table reproduced from Xie C, et al. Proc Natl Acad Sci USA. 1999;96(21):11992-7.

Mutations in the NPC Gene Lead to Accumulation of Cholesterol and
Other Lipids in Various Tissues Such as the Brain, Liver, and Spleen
• A mouse model (NPC1nmf164) of a point mutation in NPC1
has been described, which causes a single amino acid
change in a region of the NPC1 protein where ~1/3 of
mutations in patients with NPC are found. NPC1nmf164 mutant
mice demonstrate cholesterol accumulation in the liver,
spleen and brain
• Cholesterol accumulation was also evident in a mouse model
of the most common NPC1 mutation found in patients with
NPC (p.I1061T)
–

A broad range of lipids including unesterified cholesterol
accumulated in the liver

–

Cholesterol storage was observed throughout all layers of the
neocortex

Figure reproduced from Reid PC et al. J Lipid Res. 2004;45(3):582-91.
Maue RA, et al. Hum Mol Genet. 2012;21(4):730-50.

Clinical Presentation

Average Age at Diagnosis is 10 Years; Average Age at Death is 16 Years

NPC Disease US Database:
Delayed Diagnosis

50%

of patients are
diagnosed before
age 6.9 years

It can take up to 10
years for a
diagnosis

Average age at diagnosis is 10.4 years

NPC Disease US Database:
Poor prognosis

50%

Death occurs
between 8 and 25
years in most cases

of patients die
before age 12.5
years

Average age at death is 16.2 years
Garver WS, et al. Am J Med Genet. 2007; Part A 143A:1204-1211.

NPC is Often Categorized by the Age of Onset of the First Neurological
Symptoms (Early Infantile, Late Infantile, Juvenile, and Adult)
• In NPC, cholesterol accumulation in the CNS results in progressive and irreversible neuronal
degradation and neurological manifestations
• Early onset of neurological symptoms is directly linked to severity of NPC
Schematic of the main forms of NPC, with emphasis on type and age of onset of first neurological symptoms

CNS, central nervous system. Figure reproduced from Vanier MT. Orphanet J Rare Dis 2010;5:16.

The Clinical Presentation of NPC is Heterogenous and Nonspecific,
Rendering Diagnosis Challenging
• NPC has a variable presentation, including visceral, neurological, and psychiatric signs and symptoms
and can present at any age1,2
–

Younger patients tend to present predominantly with visceral manifestations

–

Neurological and psychiatric symptoms become more common with increasing age
Visceral

-Isolated unexplained
splenomegaly
-Hepatomegaly/splenomegaly
-Prolonged neonatal cholestatic
jaundice
-Hydrops fetalis or fetal ascites
-Pneumopathologies (aspiration
pneumonia, alveolar lipidosis,
interstitial lung involvement)
-Mild thrombocytopenia

Neurological

-Vertical supranuclear gaze palsy
-Gelastic cataplexy
-Ataxia
-Dystonia
-Dysarthria
-Dysphagia
-Delayed developmental
milestones
-Seizures
-Hearing loss

1. Vanier MC. Orphanet J Rare Dis. 2010;5(16):1-18. 2. Patterson MC, et al. Orphanet J Rare Dis. 2013,8:12.

Psychiatric

-Developmental

delay
-Pre-senile cognitive decline
-Organic psychosis
-Disruptive/aggressive
behavior
-Progressive development of
treatment-resistant
symptoms

Neurological Manifestations Can Lead to Mortality
• Progressive neurodegeneration results in disabling neurological and psychological
symptoms like ataxia, dystonia, hypotonia,vertical supranuclear gaze palsy, gelastic
cataplexy, dysarthria, dysphagia, cognitive decline, pre-senile cognitive
decline/dementia and psychosis1
• Mortality usually results from the neurological manifestations of the disease, most
commonly dysphagia (and consequent aspiration pneumonia), and is exacerbated by
the delays in diagnosis2

1. Patterson MC, et al. Orphanet J Rare Dis. 2013,8:12. 2. Walterfang M, et al. Orphanet J Rare Dis. 2012;7:76.

Diagnostic Delay Exacerbates Morbidity and Mortality
• Dysphagia is a common neurological symptom in NPC patients (prevalence ~55%)1

• The risk of aspiration pneumonia is significantly increased in patients with dysphagia,2
and the most common reported cause of death in patients with NPC is
bronchopneumonia2,3

• The average delay in diagnosis from onset of neurological manifestations is 4.1 years4

1. Walterfang M, et al. Orphanet J Rare Dis. 2012;7:76. 2. Jan MM, et al. J Child Neurol. 1998;13:75-8. 3. Kelly DA, et al. J Pediatr. 1993;123:242-7. 4. Patterson MC, et al. Orphanet J Rare Dis. 2013,8:12.

Age at Neurological Onset and Age at Diagnosis for Patients With
Neurological Manifestations From NPC
Age at neurological
onset, years

Age at diagnosis, years

n

Mean (SD)

Patients with neurological
manifestations

145

10.9 (9.8)

140

15.0 (12.2)

4.1

Early infantile (<2 years)

16

0.8 (0.6)

16

1.0 (1.0)

0.2

Late infantile (2 to <6 years)

45

4.2 (1.3)

43

8.2 (7.4)

4.0

Juvenile (6 to <15 years

45

9.7 (2.8)

41

13.8 (5.0)

4.1

Adolescent/adult (≥15 years)

39

24.0 (8.9)

39

29.7 (10.0)

5.7

SD, standard deviation.
Table reproduced from Patterson MC, et al. Orphanet J Rare Dis. 2013,8:12.

n

Mean difference,
years

Mean (SD)

Progressive Hepatosplenomegaly is Present in ~50% of Patients, With
Variable Intensity
• Neurological involvement defines the disease severity in most patients but is typically
preceded by systemic signs (cholestatic jaundice in the neonatal period or isolated
spleno- or hepatosplenomegaly in infancy or childhood)1,2
Neonatal jaundice

Hepatomegaly and/or splenomegaly
Patients, %

Patients, %
100
80

Overall neonatal
jaundice during
infancy (49/126; 39%)

100
80

60

60

40

40

20

20

0

0

1. Patterson MC, et al. Orphanet J Rare Dis. 2013,8:12. 2. Varnier MT. Orphanet J Rare Dis. 2010;5:16.

Overall hepatomegaly during
infancy (50/127; 39%);
splenomegaly (69/127; 54%)

Clinical Diagnosis

Highly Variable Clinical Presentation Leads to a Lack of
Detection and Diagnosis
• Low disease awareness and heterogeneous clinical presentation impedes diagnosis,
often resulting in misdiagnosis and/or delay in therapy initiation

Symptom progression from onset of disease and common misdiagnoses of NPC

Figure reproduced from Klunemann H, et al. Eur Neuro Rev. 2011;12-15.
Klunemann H, et al. Eur Neuro Rev. 2011;12-15.

Diagnosis of NPC is Often Delayed, and NPC is Often Confused
With Other Diseases
• Time to diagnosis is limited by the symptomology exhibited by patients and speed of recognition by
healthcare professionals

• Greater awareness of the disease and its manifestations among healthcare professionals may
expedite referral to specialist centers
Average Delay in NPC Diagnosis of 4-6 Years

Average time to diagnosis from symptom onset:
Visceral symptoms

Developmental delay

9 months
•
•
•

Hepatomegaly
Splenomegaly
Jaundice

Klunemann H, et al. Eur Neuro Rev. 2011;12-15.

Psychiatric symptoms

6 years
•
•
•

Clumsiness
Ataxia
Declining academic performance

Up to 19 years
•
•
•

Hallucinations
Aggressive behaviour
Paranoia (often in
teens)

Diagnosis of NPC is Often by Clinical Exclusion and Confirmatory
Biomarker Testing in Addition to Important Genetic Evaluation
• Laboratory tests include biochemical testing of intracellular cholesterol homeostasis, DNA tests for NPC gene

mutations, and skin biopsy
•

•

A key diagnostic test is demonstration of impaired
intracellular cholesterol transport by filipin staining of
fibroblasts cultured from patient skin biopsies1,2
•

NPC+ cells show up as strongly fluorescent cholesterolfilled perinuclear vesicles under fluorescence microscopic
examination1,2

•

This is the classical cholesterol storage pattern,
demonstrated in >80% of cases3

•

Other patients show a variant biochemical phenotype with
less pronounced and more variable cholesterol storage1-3

Visualization of unesterified cholesterol by filipin staining of
fibroblasts from a typical patient with NPC1 mutations (A) and
a typical patient with NPC2 mutations (B)

DNA tests for NPC1/NPC2 mutation should be performed in
parallel with filipin staining1
•

Although significant advances have been made in genetic
sequencing of NPC1/NPC2, filipin staining remains the
primary diagnostic test

Figure reproduced from Vanier MT, Latour P. Method Cell Biol 2015;126:357-75

1. Patterson MC, et al. Mol Genet Metab. 2012;106:330-44. 2. Vanier MT, et al. Biochim Biophys Acta. 1991;328-37. 3. Patterson MC, et al. Orphanet J Rare Dis. 2013;8:12.

Diagnosis of NPC is Often by Clinical Exclusion and Confirmatory
Biomarker Testing in Addition to Important Genetic Evaluation, cont.
• Biomarkers could potentially substantially
reduce diagnostic delays and may also
prove useful in establishing disease
severity and monitoring disease
progression and response to therapeutic
interventions1
• Recently, biomarkers have been
developed to diagnose NPC that are less
invasive, cost-effective, and easier to
perform than conventional NPC
diagnostic methods1

Minimally Invasive Biomarkers Investigated in NPC
Cholestane-3β,5α,6β-triol2,3

24(S)-hydroxycholesterol3

Lysosphingomyelin4

Bile acids5

Lysobisphosphatidic acid 6

1. Papandreou A, et al. Ther Adv Neurol Disord. 2016;9(3):216-29. 2. Kannenberg F, et al. J Steroid Biochem Mol Biol. 2017;169:54-60. 3. Porter FD, et al. Sci Transl Med. 2010;2(56):56ra81.
4. Welford RWD, et al. PLoS One. 2014;9(12):e114669. 5. Mazzacuva F, et al. FEBS. 2016;590(11):1651-62. 6. Liu N, et al. Toxicol Appl Pharmacol. 2014;279(3):467-76.

NPC Suspicion Index is a Simple-to-Use and Interactive Screening Tool
• Experts recommend initiating specific therapy at the first
appearance of neurological symptoms
• Given the heterogeneous presentation of NPC,
international experts developed a simple and reliable
screening tool which aims to:
–

Identify patients who should undergo testing
for NPC

–

Raise awareness of the key signs and symptoms of
NPC

–

Exclude patients unlikely to have NPC

–

In patients >4 years, prominent leading
manifestation–associations were ataxia with
dystonia, dysarthria/dysphagia, and cognitive
decline. Psychosis was associated with
dysarthria/dysphagia but also with cognitive decline
and treatment-resistant psychiatric symptoms.

Available at: http://www.npc-si.com/symptoms/. Accessed November 2, 2017.

Making a Diagnosis in Pediatric Patients

Patients May See Numerous Specialists Prior to Receiving a
Diagnosis of NPC
• Absence of a symptom checklist for identifying metabolic disease often means a lengthy wait before
patients receive a diagnosis

.
Birth

19+ years

1

1st contact for patients
(whose symptoms have
been missed at birth) is
Family Physician or
Pediatrician oftenly
who has little or no
experience of NPC

2

For patients with classic
symptoms, recognition at
birth leads to referral to a
Gastroenterologist who
may rapidly diagnose NPC

3

Where these symptoms are
missed, patients remain in
General Medical Care,
only achieving referral for
treatment of individual
symptoms as they become
severe

4

Patients are cared for by
several specialists at the
same time, most of whom
have little understanding of
the implications of the
symptoms outside their
specialty

5

Family Physician or
Pediatrician may
refer the patient for
counselling for mental
illness or emotional
disorders

6

Symptoms such as
hallucinations, aggressive
behavior, or incoherent speech
usually result in a relatively
rapid referral to a Psychiatrist
and initiation of treatment for
schizophrenia or bipolar
disorder

Niemann-Pick type C disease: Journey to Diagnosis. http://rqmo.org/wp-content/uploads/2015/01/Niemann-Pick-Enqu%C3%AAte-anglais.pdf. Accessed November 2, 2017.

Patients in Psychiatric care
already have a ‘diagnosis’
accounting for a variety of
symptoms. As a result, the
patient can be hidden in
psychiatric care, seeing a
series of specialists in mental
illness who have little reason
to suspect misdiagnosis

Pediatricians Have a Fundamental Role Linking Symptoms Together to
Facilitate a Fast Differential Diagnosis1-3
Presentation

• History of prolonged neonatal cholestasis, hepatomegaly, and presence of splenomegaly
in combination with clumsiness, frequent falls, or developmental delay could indicate NPC
• Symptoms might present at different times; some symptoms may appear to have been
resolved
• Patient medical histories can often reveal unexplained cholestatic jaundice
• Although vertical supranuclear gaze palsy is a characteristic symptom of NPC and is
present in nearly all cases, it is often missed, especially among younger patients
Hepatosplenomegaly?
Differential Diagnosis

+
Ataxia?

+
Developmental delay?

+
Eye movement abnormalities?

=
Consider NPC
1. Patterson MC, et al. Mol Genet Metab. 2012;106(3):330-44. 2. Vanier MC, et al. Orphanet J Rare Dis. 2010;5(16):1-18. 3.Wijburg FA, et al. Neurology. 2012;78(20):1560-7.

In Some Cases, the Disease May Never be Detected or
May be Misdiagnosed ( Adapted from Alobaudy H. Int J Ped. 2015;1-10 )
Age

Pre-/perinatal period <3m

Early infantile (3m-2y) +
Late infantile period
(2-6y)

Late infantile +
.
Juvenile
period (6-15y)

Juvenile period (6-15y)

Presenting
symptoms

Common differential diagnoses

Fetal hydrops

Chromosomal disorders.
Congenital heart malformations

Hemoglobinopathies .
Infectious diseases

Prolonged neonatal
cholestatic jaundice

Idiopathic hepatitis. Biliary atresia .Galactosemia
Alpha 1 antitrypsin deficiency.Bile acid synthesis disorders

Cystic fibrosis .Tyrosinemia type I.
Peroxisomal disorders. Kernicterus
(Bilirubin encephalopathy)

Isolated splenomegaly
or
hepatosplenomegaly

Mucopolysaccharidosis .Oligosaccharidosis.
Sphingolipidosis (Gaucher .Niemann-Pick A and B)

Lipid storage disease (LAL-D).
Glycogen storage disorders

Dystonia

Respiratory chain disorders .Pyruvate dehydrogenase
deficiency .Vitamin E deficiency .Glucose transporter 1
deficiency

Homocystinuria .Wilson disease,
Urea cycle defects. Organic aciduria

Ataxia

Vitamin E deficiency.
Autosomal recessive cerebellar ataxia (ARCA)

Mitochondrial disorders.
Friedreich’s ataxia

Vertical supranuclear
gaze palsy ( usually
downgaze first )

Progressive supranuclear palsy . Multiple system
atrophy .Dementia with Lewy bodies.
Spinocerebellar ataxia .Tay-Sachs.
Thyroid disorders (usually up gaze first)

Wernicke encephalopathy.
Sporadic Creutzfeldt-Jakob.
Huntington’s. Wilson.Vitamin B12
deficiency .Kernicterus.
Whipple disease (3 months to 81 years.)

Gelastic cataplexy

Gelastic seizures

Narcoleptic pentad

Psychosis

Hysteria, schizophrenia .Wilson disease.
Urea cycle defect. Homocystinuria

Acute intermittent porphyria.
Cerebrotendinous xanthomatosis

Clinical Management

There is Currently No Cure for NPC
• Supportive therapies are variably effective for the alleviation of numerous clinical problems associated
with the disease1
• Current therapeutic approaches focus on health-related quality of life, via multidisciplinary control of
symptoms and their onset 2
Management strategies include non-specific, symptomatic treatments and NPCspecific therapies1,3
Symptomatic therapies aim to improve a patient’s quality of life.
However, they have no impact on disease progression or
long-term outcomes1
Recent advances in the understanding of NPC pathophysiology
have led to the development of an NPC–specific treatment,
Miglustat, that can slow down the progression of the disease 1,4

Early diagnosis of NPC means that patients can access treatment and is crucial
for timely intervention1
1. Patterson MC, et al. Mol Genet Metab. 2012;106(3):330-44. 2. Wraith JE, Imrie J. Understanding Niemann-Pick disease type C and its potential treatment. 2007. Blackwell Publishing, Oxford UK.
3. Vanier MC, et al. Orphanet J Rare Dis. 2010;5(16):1-18. 4. Pineda M, et al. Mol Genet Metab. 2009;98:243-249.

Current Approaches Target Symptoms and Focus on
Health-related Quality of Life
• Symptomatic management includes gastrostomy to maintain caloric intake, antiepilepsy
drugs to prevent seizures, tricyclic antidepressants to control cataplexy, and
anticholinergic drugs to treat dystonia and tremors

• Most treatments for NPC focus on symptomatic management to improve patient’s quality
of life1

1. Patterson MC, et al. Mol Genet Metab. 2012;106(3):330-44.

Current Approaches Target Symptoms and Focus on
Health-related Quality of Life, cont.
Symptom

Neurological
manifestations

Seizures
Cataplexy

Treatment approach
• Antiepileptic drugs
• Tricyclic antidepressants or CNS stimulants

Dystonia and tremor

•
•

Anticholinergic drugs
Other drugs that can be effective: trihexyphenidyl, benzodiazepines, botulin toxin (selected
cases), gamma-aminobutyric acid derivatives (advanced dystonia)

•
•

Softening or thickening of food
Gastrostomy

•

Oral atropine, parotid/submandibular injections of botulinum toxin, hydroscine patches, or
glycopyrronium bromide

•

Melatonin or positive airway pressure

•
•

Support services
Miglustat may stabilize cognitive decline

•

Atypical antipsychotics and regular neurological monitoring to minimize aggravation of
preexisting dystonia

Catatonia
Bipolar disorder
Depression

•
•
•

Electroconvulsive therapy
Mood stabilizers (eg, sodium valproate)
Selective serotonin reuptake inhibitors

Gastrointestinal disturbances

•
•

Antipropulsive agents (eg, loperamide) for diarrhea
Bowel monitoring to prevent constipation in affected patients

•

Aggressive bronchodilation and, in some cases, chest physical therapy

Dysphagia
Drooling
Sleep disturbances

Cognitive impairment
Psychosis
Psychiatric illness

Systemic
manifestations
Primary lung involvement

CNS, central nervous system.
Patterson MC, et al. Mol Genet Metab. 2012;106(3):330-44.

There Are Currently No Treatments For NPC That Directly Address The
Pathophysiology Of Disease
•

In the United States, Miglustat was approved only for the treatment of mild to moderate Type I Gaucher disease in adults who cannot
use enzyme replacement1

• Outside the United States, Miglustat is approved for the treatment of NPC. Miglustat has demonstrated limited efficacy in stopping or
delaying the progression of NPC in the majority of patients
Inhibition of glucosylceramide synthase with Miglustat

•

Miglustat is an iminosugar that reversibly inhibits the enzyme
glucosylceramide synthase, the first committed step in
glycosphingolipid synthesis2

•

Although not approved in the United States for NPC,3
Miglustat is approved in Europe and other countries for the
treatment of progressive neurological manifestations in adult
and pediatric patients with NPC4

•

Miglustat was approved in Europe based on the results from
a small randomized controlled trial and its long-term
extension studies, as well as a retrospective observational
cohort study3

Figure reproduced from Ficiciogly C. Ther Clin Risk Manag, 2008;4(2):425-31.
1. Center for Drug Evaluation and Research Approval Letter. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-348_Zavesca_Approv.pdf. Accessed November 2, 2017. 2. Platt FM, et al. J Biol
Chem. 1994;269(11):8362-5. 3. Zavesca (miglustat) (prescribing information). 2014; Actelion Pharmaceuticals US Inc; South San Francisco, CA. 4. Zavesca (miglustat) Summary of Product Characteristics.
2016; Actelion Registration Ltd, London, UK.

VTS-270 Re-Establishes the Cell’s Ability to Transport and Regulate
Cholesterol
Preliminary results from a Phase I/IIa study showed that administration of VTS-270 slowed and changed the course of disease progression

Phase II/III Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease (NCT02534844)

• Efficacy and safety of VTS-270 in patients (aged 4-21 years) with neurologic manifestations of NPC disease
•

Onset of neurological symptoms prior to 15 years of age and confirmed diagnosis of NPC1 determined by either:
•
•
•

•
•

2 NPC1 mutations
Positive filipin staining and ≥1 NPC1 mutation
Vertical supranuclear gaze palsy plus either: one NPC1 mutation, OR positive filipin staining or oxysterol levels consistent with NPC disease and no
NPC2 disease mutations

Approximately two-thirds of patients will receive VTS-270 and the remaining study participants will receive sham control
Aim to enroll 51 patients, estimated completion date: March 2018

Primary outcome measure
(52 weeks)
• NPC Clinical severity score

Ory DS, et al. Lancet. 2017;390:1758-1768.

Secondary outcome measures
(52 weeks)
• Clinician and Caregiver Global Impression of Change
• Time to get up and go test
• 9-hole peg test
• Percentage of patients with clinical worsening
• European quality of life score

Other outcome measures
(52 weeks)
• CSF biomarkers
• Plasma protein biomarkers

Available Therapies Target One or More Pathological Features of NPC
•

Currently, therapies are targeted at one or more
pathologic features of NPC, and combinations of
these small-molecule drugs have shown enhanced
clinical benefit

•

Individual treatments aim to:

–

(1) reduce the accumulation of offending
metabolites

–

(2) bypass defective metabolic pathways

–

(3-5) enhance a cell’s resistance to disease

–

(6) increase/rescue function of existing NPC
proteins .Molecular chaperone therapy only
works with certain mutations : Gaucher's
disease, Fabry disease, Pompe disease and
Late-onset Tay-Sachs disease.

–

(7-8) correct the primary metabolic defects

–

(9) improve lysosomal function

HPBCD, 2-hydroxypropyl-beta-cyclodextrin.
Davidson CC, et al. US Neurology. 2010;88-94.

Case Presentation

Patient Presentation

Patient History

•
•
•
•
•

14-year-old female
Hepatomegaly occurred at approximately age 6 years
Developed dyspraxia, which manifested as slow running at the age of 8 years
Bilateral dystonia was observed at age 10 years
Scholastic achievement began to decline at age 12 years

Patient Presentation

•
•
•
•

Recent unexplained frequent falls and seizures reported by parents
Coupled with neurological regression
Hypotonia
Facial dyskinesia

Adapted from: Lorenzoni PJ, et al. Arq Neuropsiquiatr. 2014;72(3):214-218.

Audience Question

How would you manage the patient at this point?
1. Referral for a neurological assessment
2. Referral for further testing (ie, MRI, laboratory analysis, genetic analysis)
3. Follow-up within 3 to 6 months
4. Consider a differential diagnosis
5. Other

MRI, magnetic resonance imaging.
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1. Referral for a neurological assessment
2. Referral for further testing (ie, MRI, laboratory analysis, genetic analysis)
3. Follow-up within 3-6 months
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5. Other

MRI, magnetic resonance imaging.

ANSWER

Diagnostic Investigation

Diagnostic tests

Result

Abnormal brain MRI

+

High chitotriosidase level

+

Sea-blue histiocytes at bone marrow

+

Foamy cells at bone marrow

+

Filipin staining

+

Bone marrow biopsy showing sea blue histocytes with MayGrumwalld-Giemsa staining or Niemann-Pick cells

Results
•

Diffuse cerebral and cerebellar atrophy was observed

•

Serum chitotriosidase levels were above normal limits

•

Bone marrow biopsy showed sea-blue histiocytes and foamy cells

•

Skin fibroblast culture was atypical

Adapted from: Lorenzoni PJ, et al. Arq Neuropsiquiatr. 2014;72(3):214-218.

Audience Question

What would your differential diagnosis be?
1. Gaucher’s disease
2. Niemann-Pick disease Type C
3. Multiple sclerosis
4. Other
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What would your differential diagnosis be?
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2. Niemann-Pick disease Type C
3. Multiple sclerosis
4. Other

ANSWER

Differential Diagnosis

Suspected NPC

•

Genetic testing revealed compound heterozygotic mutations in the NPC1 gene on alleles 1 and 2
(A764V and A1035V, respectively)

Early treatment in the disease course is associated with
improved responses,
highlighting the need for rapid diagnosis

Adapted from: Lorenzoni PJ, et al. Arq Neuropsiquiatr. 2014;72(3):214-218.

Summary
• Early diagnosis is strongly influenced by symptoms presentation and speed of symptoms
recognition
• There is a low awareness about the metabolic storage diseases, such as NPC
• There is a need for improved education among healthcare professionals so that they can
recognize the link between the symptoms that will lead to the diagnosis of NPC
• There is a need for a greater focus on raising awareness of the classic symptoms in infants and
for proactive testing of newborns with splenomegaly and / or hepatomegaly and severe jaundice
before the symptoms subside
• For those patients whose first symptoms are learning and behavioral difficulties, pediatricians
need to recognize and link symptoms together and think of a wider picture to allow
multispecialty collaboration.
• Unexplained ‘’ Hepatosplenomegaly + Ataxia + Developmental delay + Eye movement
abnormalities consider NPC ‘’

Summary

• Currently, there are no treatments for NPC that directly address the pathophysiology of
disease; current management approaches of NPC have shown limited efficacy and focus
on symptomatic treatment strategies

• VTS-270 re-establishes cholesterol homeostasis by bypassing the NPC1/NPC2
pathway
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Available from: https://www.ncbi.nlm.nih.gov/books/NBK1296/. Accessed February 9, 2017.

•

Vanier TM. Niemann-Pick Disease Type C. Orphanet J Rare Dis. 2010;5:6.
Available at: http://www.ojrd.com/content/5/1/16.

•

Patterson MC. Overview of Niemann-Pick Disease. UpToDate, Inc. Aug 02, 2016.
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NORD Member Organizations

Other Organizations

•

•

CLIMB (Children Living with Inherited Metabolic Diseases)
Email: enquiries@climb.org.uk
Website: http://www.CLIMB.org.uk

•

Genetic and Rare Diseases (GARD) Information Center
Website: http://rarediseases.info.nih.gov/GARD/

•

GOLD, Global Organisation For Lysosomal Diseases
Email: enquiries@goldinfo.org
Website: http://www.goldinfo.org

National Niemann-Pick Disease Foundation, Inc.
Email: nnpdf@nnpdf.org
Website: http://www.nnpdf.org

Questions?

Thank you

